-- New agreement marks the second collaboration between Merck and
DARMSTADT, Germany, Nov. 13, 2013 /CNW/ - Merck Serono, the biopharmaceutical division of Merck, today announced
that a global licensing, co-development, and commercialization
agreement for BeiGene-290 has been signed with BeiGene Co., Ltd., a
biotech research and development company in Beijing, China. The
compound, which is a potent poly (ADP-ribose) polymerase (PARP)
inhibitor for the treatment of cancer, is currently in preclinical
development and is expected to enter clinical development next year.
This is the second collaboration agreement between the two companies
PARP inhibitors are thought to target an enzyme family, poly
(ADP-ribose) polymerase, which is involved in a number of cellular
processes, including DNA repair and programmed cell death.
Under the terms of the collaboration, BeiGene will be responsible for
the development and commercialization of BeiGene-290 in China, and
Merck will be responsible for the development and commercialization of
BeiGene-290 for the rest of the world. BeiGene will receive an
undisclosed upfront payment and is eligible to receive further payments
of up to EUR 170 million (US$ 232 million) for the achievement of
clinical development and potential commercial milestones in both the
People's Republic of China and rest of the world, as well as royalties
on net sales.
"We are delighted to announce an expansion of our strategic partnership
with BeiGene. Today's announcement highlights our commitment both to
establishing strong R&D partnerships in China but also to our partner
BeiGene, a preeminent Chinese life sciences company focused on
discovering and developing innovative oncology drugs," said Dr. Susan
Jane Herbert, Head of Global Business Development and Strategy for
Merck Serono, the biopharmaceutical division of Merck.
John Oyler, CEO of BeiGene said: "We are very much looking forward to
expanding further our collaboration with Merck to include BeiGene-290.
This collaboration helps to accelerate the global development and
commercialization of this China-discovered oncology innovation,
something BeiGene could not have achieved alone. Furthermore this deal
and Merck's previous deal with BeiGene to develop the second
generation, China-discovered BRAF inhibitor, BGB-283, demonstrate
Merck's deep commitment to China and external innovation."
Both companies were recently awarded the 2013 BayHelix-Elsevier Award
for Alliance of the Year. This award recognizes a ground-breaking
pharmaceutical collaboration agreement involving a Chinese entity - one
that is centered on advancing the future of science and pharmaceutical
innovation. It is a significant recognition for both organizations,
underscoring a shared commitment to establishing strategic partnerships
that accelerate the delivery of differentiated new therapies to people
living with serious unmet medical needs.
About BeiGene (Beijing), Co., Ltd.
BeiGene is a Chinese novel R&D oncology company focusing on discovering,
developing and commercializing innovative oncology therapeutics. With a
team of around 150 scientists and staff, its pipeline is comprised of
novel oral small molecules and monoclonal antibodies for cancer.
BeiGene Ltd. is a Cayman Islands exempted company that is an investor
in and collaborator with BeiGene (Beijing), Co. Ltd.
For more information please visit: http://www.beigene.com.
About Merck Serono
Merck Serono is the biopharmaceutical division of Merck. With
headquarters in Darmstadt, Germany, Merck Serono offers leading brands
in 150 countries to help patients with cancer, multiple sclerosis,
infertility, endocrine and metabolic disorders as well as
cardiovascular diseases. In the United States and Canada, EMD Serono
operates as a separately incorporated subsidiary of Merck Serono.
Merck Serono discovers, develops, manufactures and markets prescription
medicines of both chemical and biological origin in specialist
indications. We have an enduring commitment to deliver novel therapies
in our core focus areas of neurology, oncology, immuno-oncology and
For more information, please visit http://www.merckserono.com.
All Merck Press Releases are distributed by e-mail at the same time they
become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading pharmaceutical, chemical and life science company
with total revenues of EUR 11.2 billion in 2012, a history that began
in 1668, and a future shaped by approx. 38,000 employees in 66
countries. Its success is characterized by innovations from
entrepreneurial employees. Merck's operating activities come under the
umbrella of Merck KGaA, in which the Merck family holds an
approximately 70% interest and free shareholders own the remaining
approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was
expropriated and has been an independent company ever since.
SOURCE: Merck Sereno
For further information:
Your Contact: Dr. Raphaela Farrenkopf, Phone +49-6151-72-2274, Email firstname.lastname@example.org